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Background: After a peak in the late 1980s, cancer mortality in Europe has declined by ∼10% in both sexes up to the
early 2000s. We provide an up-to-date picture of patterns and trends in mortality from major cancers in Europe.
Methods:We analyzed cancer mortality data from the World Health Organization for 25 cancer sites and 34 European
countries (plus the European Union, EU) in 2005–2009. We computed age-standardized rates (per 100 000 person-
years) using the world standard population and provided an overview of trends since 1980 for major European countries,
using joinpoint regression.
Results: Cancer mortality in the EU steadily declined since the late 1980s, with reductions by 1.6% per year in 2002–
2009 in men and 1% per year in 1993–2009 in women. In western Europe, rates steadily declined over the last two
decades for stomach and colorectal cancer, Hodgkin lymphoma, and leukemias in both sexes, breast and (cervix) uterine
cancer in women, and testicular cancer in men. In central/eastern Europe, mortality from major cancer sites has been
increasing up to the late 1990s/early 2000s. In most Europe, rates have been increasing for lung cancer in women and for
pancreatic cancer and soft tissue sarcomas in both sexes, while they have started to decline over recent years for multiple
myeloma. In 2005–2009, there was still an over twofold difference between the highest male cancer mortality in Hungary
(235.2/100 000) and the lowest one in Sweden (112.9/100 000), and a 1.7-fold one in women (from 124.4 in Denmark to
71.0/100 000 in Spain).
Conclusions:With the major exceptions of female lung cancer and pancreatic cancer in both sexes, in the last
quinquennium, cancer mortality has moderately but steadily declined across Europe. However, substantial differences
across countries persist, requiring targeted interventions on risk factor control, early diagnosis, and improved
management and pharmacological treatment for selected cancer sites.
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introduction
After a peak in the late 1980s, cancer mortality in Europe has
declined by ∼10% up to the early 2000s [1, 2]. The major
components of these favorable trends in men were the fall in
lung and other tobacco-related neoplasms, together with the
persistent decline in gastric and a more recent decline in
colorectal cancer mortality rates. In women, the major
contributors were the persistent decline in cervical cancer and
the favorable trends in breast and colorectal cancer mortality,
particularly in northern and western Europe. Favorable trends
were also observed for leukemias, Hodgkin lymphoma,
testicular cancer, and a few other neoplasms amenable to
treatment. We have predicted that most of these trends will be
maintained up to the most recent years [3].
There were, however, persistent marked differences in cancer
mortality rates and trends within Europe, with generally less
favorable trends in Russia, Romania, and other central and
eastern European countries, compared with western Europe [1,
4]. These unfavorable trends were in part due to a greater
smoking prevalence and other unfavorable lifestyle habits in this
area of the continent, but also to some delays in effective disease
management, including diagnosis and therapy [5].
Monitoring of mortality patterns and trends is important for
planning and evaluating programs for cancer control. Mortality
is a synthetic and valid indicator which allows to assess the
impact of preventive and therapeutic strategies against cancer.
Moreover, it has long been available, reliable, and comparable
across Europe. Thus, in order to provide an up-to-date picture
of patterns and trends in mortality from major cancers in
Europe, here we consider data for the quinquennium 2005–
2009, together with an overview of trends since 1980.
materials and methods
We extracted ofﬁcial death certiﬁcation numbers for 25 cancer sites in 34
European countries for the period 1980–2009 from the World Health
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Organization (WHO) database as available on electronic support [6]. The
European Union (EU) was deﬁned as the 27 member states as in January
2007, with the exclusion of Cyprus, for which data were available only for a
limited number of years. Data for testicular and kidney cancer in
Switzerland for the years 1995–2007 were provided by the Swiss National
Institute for Cancer Epidemiology and Prevention [7].
During the calendar period considered, three different revisions of the
International Classiﬁcation of Diseases (ICD) were used [8–10 ]. Classiﬁcation
of cancer deaths was re-coded, for all calendar periods and countries,
according to the 10th revision of the ICD. Because the change from the 8th to
the 10th revision of the ICD in 1995 in Switzerland caused discontinuities in
trends, Swiss data for a few neoplasms (i.e. prostate, testis, bladder, and
kidney) between 1980 and 1995 were corrected using age-speciﬁc factors [11].
To improve validity and comparability of data throughout different countries,
we pooled together all intestinal sites (mainly colon and rectum), all uterine
cancers (cervix and corpus), all skin neoplasms (including melanoma), all
non-Hodgkin lymphoma, and all connective and soft tissue sarcomas. We did
not consider long-term trends in pleural mesothelioma mortality, since
pleural mesothelioma was not available separately from other pleural
neoplams in the 9th revision of the ICD, and the combination of the 10th ICD
codes C45.0 (mesothelioma) and C38.4 (other malignant neoplasms of the
pleura) is inﬂuenced by misclassiﬁcation with lung cancer, thus introducing
spurious trends in several countries. Neoplasms of the brain or nerves were
also not considered, since for several countries it was not possible to
consistently pool together subsequent revisions of the ICD. Data for liver
cancer—presented only in the tables—should be taken with due caution, due
to the difﬁculty in distinguishing primary from unspeciﬁed liver cancers in
several countries [12].
In a few countries, mortality data were missing for one or more calendar
years. No interpolation was made for missing data except for the deﬁnition
of the EU rates, where, when data were not available for one or more years
within a country, the nearest available data (i.e. generally that of the previous
or subsequent year) were replicated.
We obtained estimates of the resident population, based on ofﬁcial
censuses, from the sameWHO database [6]. Population data for France in
2009 and for and Portugal and the UK in 2010 were obtained from the
EUROSTAT database, since these data were not available in the WHO
database [13]. From the matrices of certiﬁed deaths and resident populations,
we computed age-speciﬁc rates for each 5-year age group (from 0–4 to 80–84,
and ≥85 years) and calendar period. We then computed age-standardized
rates per 100 000 person-years (at all ages and truncated 35–64 years) using
the direct method and based on the world standard population [14].
To identify signiﬁcant changes in trends for the EU as a whole and 24
selected countries (excluding countries with less than 2 000 000 inhabitants
and a few other entities such as Belarus, Belgium, Bulgaria, Croatia, Slovakia,
because of difﬁculties in evaluating long-term trends), we carried out
joinpoint regression analysis, which allows to identify the best-ﬁtting points
(the ‘joinpoints’) where a signiﬁcant change in the linear slope (in a log
scale) of the trend is detected [15, 16]. For each of the identiﬁed trends, we
also computed the estimated annual percent change (APC) by ﬁtting a
regression line to the natural logarithm of the rates using calendar year as a
regression variable.
results
Table 1 gives the average annual number of deaths and the
overall age-adjusted (world population) mortality rates from
selected cancers per 100 000 men in 34 European countries plus
the EU as a whole in 2005–2009. Male total cancer mortality
rates in the EU were 153.6/100 000. The highest rates were in
central and eastern European countries, including in particular
Hungary (235.2/100 000), Croatia, Poland, and Baltic countries
(around 200/100 000). In Russia, total cancer mortality in men
was 184.0/100 000. The highest rates in western Europe were in
France, Scotland, and Denmark (around 160/100 000); other
major western European countries (Spain, Italy, the UK, and
Germany) had rates between 138 and 152/100 000. The lowest
rates (113 to 127/100 000) were in most Nordic countries and
Switzerland. With reference to major cancer sites, male
mortality rates across Europe ranged from 4.3 in Sweden to
24.6/100 000 in Russia for stomach cancer, from 11.2 in Greece
to 33.0/100 000 in Hungary for intestinal cancer, from 6.0 in
Portugal to 11.0/100 000 in Hungary for pancreatic cancer, from
19.3 in Sweden to 72.6/100 000 in Hungary for lung cancer, and
from 8.9 in Italy to 20.8/100 000 in Estonia for prostate cancer.
Table 2 gives corresponding ﬁgures in women. Total cancer
mortality rate in EU women in 2005–2009 was 90.8/100 000.
The range of variation was between 71.0/100 000 in Spain and
124.4 in Denmark, but there was no clear east–west gradient.
Besides Denmark, female cancer mortality rates were over 100/
100 000 in Hungary, Poland, Ireland, the Czech Republic, the
Netherlands, and the UK. The lowest rates (below 85/100 000)
were in Mediterranean countries, Finland, and Belarus. Rates
ranged from 1.9 in France to 10.1/100 000 in Russia for
stomach cancer, from 7.1 in Switzerland to 16.6/100 000
in Hungary for intestinal cancer, from 3.5 in Belarus to
30.1/100 000 in Scotland for lung cancer, from 12.7 in Spain
to 21.3/100 000 in Denmark for breast cancer, and from 3.1
in Belarus to 7.2/100 000 in the Czech Republic for
pancreatic cancer.
Figure 1 shows the joinpoint analysis of trends in mortality
rates (at all ages and truncated 35 to 64 years) from 23 cancer
sites plus all neoplasms in EU men and women between 1980
and 2009. Total cancer mortality in EU men reached a peak in
the late 1980s and declined thereafter, with an APC of −0.1%
between 1987 and 1993, of −1.2% between 1993 and 2002, and
of −1.6% between 2002 and 2009 overall, and of −1.7% per year
between 1993 and 2009 in middle age. In EU women, overall
cancer mortality declined over most of the period considered,
with an APC of about −1% between 1993 and 2009, both at all
ages and in middle age. Steady declines in mortality were
observed over the period 1980–2009 for stomach cancer,
Hodgkin lymphoma, and leukemias in both sexes, uterine
cancer in women, and testicular cancer in men. For the latter
neoplasm, however, the rates tended to level off in the last
decade, particularly in middle-aged men. Favorable trends were
observed since the early 1990s for most other cancers
considered, with an APC of −1.3% per year between 2002 and
2009 in men and of −1.7% between 1993 and 2009 in women
for intestinal cancer, of −1.8% between 1993 and 2009 for lung
cancer in men, of −1.7% between 1998 and 2009 for female
breast cancer, and of −2.5% between 2003 and 2009 for prostate
cancer. However, mortality in the EU has still been increasing
for lung cancer in women (APC = 2.2% between 2001 and 2009
at all ages, and 0.7% between 2007 and 2009 at ages 35–64), for
pancreatic cancer (APC = 0.6% between 2001 and 2009 in men,
and 1.2% between 2003 and 2009 in women), and for
connective and soft tissue sarcomas (APC = 1.8% between 2004
and 2009 in men, and 0.8% between 2000 and 2009 in women),
while mortality has started to decline over the last years only for
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Table 1. Overall age-adjusted (world population) mortality rates (ﬁrst row) and average annual number of deaths (second row) from selected cancers per 100 000 men in 35 European countries plus the European
Union in 2005–2009 (unless otherwise speciﬁed)
Oral cavity/
pharynx
Esophagus Stomach Intestines Liver Gall-
bladder
Pancreas Larynx Lung Bone Connective/
soft tissue
sarcomas
Skin Prostate Testis Bladder Kidney Thyroid HL NHL MM Leukemias All
neoplasms
ICD X C00–C14 C15 C16 C17–C21,
C26
C22.0–C22.7 C23–C24 C25 C32 C33–
C34
C40–
C41
C47, C49 C43–
C44
C61 C62 C67 C64–C66,
C68
C73 C81 C82–C85,
C96
C88,
C90
C91–C95 C00–D48
Austria 5.29 3.88 6.64 15.87 5.81 1.35 8.86 1.76 32.35 0.39 0.96 2.94 12.37 0.35 3.77 4.04 0.41 0.36 3.53 1.91 4.96 138.33
339 264 524 1247 428 107 658 120 2338 20 62 212 1111 19 322 315 29 22 271 151 375 10 480
Belarus (2007–2009) 10.71 5.59 23.62 16.92 3.62a – 7.22 6.03 47.79 – – 1.71 12.27 – 5.03 – – – 2.47 1.36 5.89 178.04
630 330 1439 1038 214a – 433 358 2863 – – 99 783 – 320 – – – 146 82 349 10 714
Belgium 4.82 5.12 5.00 16.47 3.18 0.60 7.01 2.35 50.80 0.60 0.87 2.16 12.41 0.17 5.50 3.82 0.27 0.43 3.33 2.01 4.83 153.70
401 462 506 1742 305 67 703 209 5021 47 72 197 1474 12 608 387 26 39 331 209 466 15 425
Bulgaria 5.69 2.43 12.97 20.26 8.06 0.92 8.30 6.19 43.93 1.38 0.24 2.43 10.13 0.91 5.34 3.81 0.34 0.85 2.38 0.65 3.99 156.71
341 154 907 1456 538 67 554 380 2794 77 14 165 821 44 394 245 22 46 142 43 233 10 383
Croatia 9.48 5.02 14.05 26.97 8.27a 2.25 8.88 5.61 57.06 1.45 0.60 3.53 15.62 0.62 6.30 5.80 0.29 0.39 3.65 1.70 5.21 202.01
328 180 544 1056 313a 91 331 205 2143 46 18 123 643 16 258 212 11 13 130 66 188 7611
Czech Republic 6.77 4.48 8.46 28.67 2.80 3.00 10.75 2.92 48.10 0.70 0.73 3.24 14.39 0.55 5.75 8.75 0.32 0.43 3.24 1.83 5.39 184.01
530 365 720 2485 233 261 907 233 4036 49 52 272 1323 35 518 738 27 33 272 161 441 15 545
Denmark (2005–2006) 4.73 5.89 4.73 20.21 2.65 0.65 8.45 1.84 40.10 0.53 0.83 3.25 19.51 0.38 6.59 4.50 0.27 0.26 4.11 2.38 4.91 159.26
212 284 230 1060 123 34 413 88 2014 17 34 155 1144 14 369 223 14 11 197 126 248 8112
Estonia 8.04 5.22 17.93 20.32 4.29 1.16 10.68 3.78 54.21 1.14 0.92 3.44 20.77 0.51 6.54 7.90 0.45 0.51 2.86 2.17 6.80 198.12
72 48 172 207 42 11 103 36 533 10 7 32 224 4 70 75 5 5 29 22 66 1944
Finland 2.16 2.92 5.80 11.81 4.19 1.28 8.93 0.64 28.24 0.26 1.08 2.79 14.08 0.18 3.35 3.81 0.26 0.28 4.38 2.35 3.91 115.72
95 138 285 599 206 65 437 32 1431 10 43 134 792 5 180 188 14 10 219 122 181 5801
France 6.75 5.97 5.10 15.84 7.51 0.79 7.97 2.36 41.88 0.72 0.87 2.15 12.14 0.26 5.54 4.31 0.27 0.37 3.81 2.17 5.06 161.47
3248 3147 2997 9880 4126 507 4442 1211 22 124 321 412 1191 8996 99 3582 2551 151 168 2265 1390 3006 92 425
Germany 5.28 4.80 6.95 16.35 4.11 1.38 8.36 1.68 34.99 0.39 0.80 2.07 11.96 0.30 3.79 5.07 0.33 0.24 3.36 2.09 4.56 138.02
3713 3692 5951 14 371 3448 1222 6983 1294 29 137 221 548 1648 11 716 163 3596 4393 270 181 2873 1878 3774 116 787
Greece 1.91 1.38 6.86 11.17 8.02a 1.16 6.88 2.79 46.45 1.41 0.38 1.66 10.10 0.32 6.19 2.95 0.24 1.23 1.34 1.37 5.92 136.96
194 155 821 1455 994a 142 782 323 5202 142 38 179 1571 23 863 355 29 126 144 175 741 16 327
Hungary 18.77 7.08 12.60 33.02 6.50a 2.63 10.98 6.77 72.57 0.48 0.90 3.44 12.70 0.85 6.83 5.74 0.45 0.33 3.64 1.42 6.16 235.22
1308 514 1022 2685 502a 221 852 494 5520 29 61 269 1159 50 575 450 34 21 278 116 463 18 247
Iceland 1.42 5.28 5.05 12.60 1.58 1.29 6.83 0.51 28.17 1.01 1.24 2.24 17.23 0.75 4.53 6.03 0.80 0.76 3.05 2.10 4.30 118.34
3 12 12 31 4 3 15 2 66 2 3 5 51 1 13 14 2 2 8 6 10 293
Ireland 3.37 7.36 6.78 20.35 3.11 0.48 7.37 2.00 32.95 0.57 0.73 3.42 15.58 0.25 3.69 4.27 0.29 0.35 4.36 2.68 4.96 142.41
95 218 207 633 93 15 217 59 994 15 20 104 530 6 121 127 8 10 132 84 151 4355
Italy (2006–2009) 3.56 2.22 8.89 16.53 4.93 1.92 7.61 2.46 38.39 0.61 0.82 2.10 8.88 0.23 5.56 3.71 0.34 0.48 3.87 2.19 5.24 145.64
1963 1331 6043 11 454 3129 1352 4789 1564 25 402 270 415 1254 7473 87 4303 2430 212 237 2426 1541 3240 97 528
Latvia 7.89 5.79 19.10 19.33 4.97a 1.07 10.36 5.41 53.44 1.24 0.82 3.16 20.24 0.77 7.72 7.56 0.48 0.55 3.59 1.77 5.77 198.92
119 89 313 331 79a 17 168 84 868 17 12 49 362 10 131 121 8 8 54 29 88 3238
Lithuania 9.88 6.85 19.04 19.87 1.70 0.90 10.14 6.15 51.51 0.95 0.86 2.90 20.36 0.46 6.88 8.33 0.36 0.58 3.02 1.86 5.89 199.58
207 148 445 485 40 23 233 132 1183 19 18 64 527 9 172 191 8 12 69 44 133 4635
Luxembourg 3.62 5.21 5.28 15.81 2.02 0.66 7.56 1.85 38.10 0.35 0.99 2.13 12.21 0.32 4.28 2.19 0.32 1.17 3.20 1.51 5.57 137.85
13 19 21 62 7 3 29 6 146 1 3 8 52 1 18 9 2 4 13 6 22 535
Macedonia (2006–
2009)
3.06 1.65 15.99 15.96 8.05 1.05 7.22 6.00 45.88 1.57 0.43 4.22 9.18 0.59 5.33 2.34 0.23 0.54 1.75 0.54 4.41 151.89
41 23 231 229 116 15 101 84 636 20 6 56 137 8 79 32 3 8 22 8 57 2125
Malta 3.93 3.24 7.48 15.93 2.16 1.07 8.47 1.94 32.54 0.86 1.00 1.58 8.94 0.59 5.62 4.19 0.71 0.51 4.34 1.72 4.94 127.99
13 11 27 57 7 4 30 7 116 2 3 5 34 2 22 15 2 2 15 6 16 451
Netherlands 2.79 7.71 5.95 19.58 1.82 0.88 7.62 1.22 43.03 0.50 0.90 3.28 14.82 0.27 5.14 5.45 0.23 0.36 4.08 2.34 4.54 151.07
371 1090 881 2931 256 130 1097 172 6363 51 111 430 2420 26 808 798 33 45 580 350 626 22 210
Norway 2.29 3.23 4.55 17.51 1.69 0.67 7.28 0.77 28.66 0.33 0.57 4.72 19.35 0.31 4.60 4.02 0.33 0.16 3.82 2.91 3.85 126.82
85 131 205 796 69 29 310 33 1212 10 21 190 1063 10 237 175 14 6 167 134 164 5723
Continued
A
nnals
ofO
ncology
originalarticles
Volum
e
24
|N
o.10
|O
ctober2013
doi:10.1093/annonc/m
dt301
|

Table 1. Continued
Oral cavity/
pharynx
Esophagus Stomach Intestines Liver Gall-
bladder
Pancreas Larynx Lung Bone Connective/
soft tissue
sarcomas
Skin Prostate Testis Bladder Kidney Thyroid HL NHL MM Leukemias All
neoplasms
Poland 6.15 4.40 12.94 20.73 3.70a 1.71 8.16 5.73 61.95 0.95 0.71 2.98 13.02 0.58 8.20 5.98 0.30 0.60 3.23 2.01 5.53 196.74
1591 1150 3537 5757 1000a 479 2189 1505 16 615 228 160 791 3828 131 2321 1600 82 150 850 554 1435 53 259
Portugal 6.78 5.35 14.72 21.14 4.60 1.44 5.99 4.26 28.55 0.69 0.91 1.97 13.45 0.26 4.82 2.32 0.32 0.42 3.82 1.85 4.28 144.35
534 454 1455 2261 435 151 585 366 2678 54 72 192 1697 18 543 236 30 34 363 200 413 14 149
Romania 11.39 3.57 14.68 16.73 9.85a 1.23 8.81 6.27 47.93 2.10 0.77 2.47 9.02 0.53 5.84 3.07 0.30 0.53 2.73 0.94 4.64 170.13
1645 540 2449 2853 1601a 211 1436 951 7425 308 114 399 1713 73 1024 483 47 74 400 155 686 27 091
Russia 8.24 6.07 24.60 19.53 5.50a – 8.72 5.36 51.21 – – 1.69 10.50 – 6.52 – – – 2.35 0.91 4.74 184.02
6901 5091 21 047 16 746 4637a – 7359 4518 43 385 – – 1428 9009 – 5585 – – – 1912 764 3755 155 298
Slovakia 15.62 6.48 11.70 30.77 6.19a 2.63 10.03 5.05 46.69 0.78 0.91 3.11 13.72 0.66 5.15 6.54 0.31 0.55 3.18 1.73 5.43 194.59
542 226 422 1100 214a 95 353 174 1633 26 29 110 510 22 191 230 11 18 110 63 184 6860
Slovenia 8.12 4.40 12.78 24.26 6.74a 2.62 8.83 2.93 46.93 0.57 0.63 3.78 18.98 0.51 6.50 5.26 0.31 0.34 4.10 2.24 5.18 182.14
128 72 218 419 111a 45 147 49 795 8 9 62 339 7 115 89 5 6 69 39 86 3076
Spain 4.94 4.13 8.16 18.44 6.15 1.04 6.60 3.85 42.89 0.57 0.77 1.76 10.05 0.15 7.88 3.22 0.23 0.37 3.18 1.82 4.31 151.60
1708 1519 3515 8329 2518 479 2630 1460 17 039 160 259 741 5499 45 3770 1364 95 130 1285 841 1746 63 888
Sweden 2.13 3.08 4.29 14.17 3.85a 1.70 7.43 0.49 19.27 0.38 0.91 3.47 19.26 0.16 3.96 3.97 0.29 0.21 3.53 2.49 4.08 112.94
186 283 438 1459 368a 172 716 48 1870 25 75 313 2461 9 459 394 29 17 359 262 398 11 725
Switzerland (2005–
2007)
4.47 4.71 4.35 12.36 6.01a – 6.49 0.99 29.53 – – 2.62 14.25 0.24 3.78 3.44 – – 3.45 2.23 4.18 123.76
281 313 308 911 408a – 455 69 2009 – – 169 1269 13 305 251 – – 255 162 289 8909
Ukraine (2005–2006/
2008–2009)
10.04 4.45 19.38 18.66 3.33 – 7.80 5.42 40.93 – – 1.76 9.49 – 6.28 – – – 2.21 0.72 4.98 163.28
2965 1337 6061 5983 1007 – 2385 1644 12 698 – – 524 3198 – 2059 – – – 627 218 1388 50 201
UK 2.78 8.71 5.26 16.85 3.06 0.36 6.48 1.15 33.12 0.45 0.80 2.57 14.05 0.19 4.77 4.06 0.23 0.37 4.18 2.32 4.40 138.20
1382 4934 3287 10 225 1722 222 3710 639 19 696 178 384 1398 10 179 71 3243 2299 130 173 2402 1433 2494 82 907
England and Wales 2.65 8.54 5.14 16.48 2.95 0.35 6.47 1.09 31.95 0.45 0.80 2.56 14.10 0.18 4.76 4.00 0.23 0.37 4.19 2.31 4.41 136.05
1167 4322 2879 8939 1478 193 3302 541 16 989 155 341 1235 9174 61 2897 2017 116 155 2153 1272 2232 72 989
Northern Ireland 3.02 8.28 5.66 20.12 3.08 0.46 7.55 1.32 36.36 0.66 0.67 2.39 13.21 0.14 4.13 3.76 0.24 0.28 3.45 2.93 3.62 142.33
39 113 87 293 42 7 105 19 525 7 8 34 222 2 67 53 3 3 49 44 51 2066
Scotland 4.11 10.63 6.33 19.83 4.21 0.41 6.32 1.73 44.29 0.47 0.89 2.79 13.78 0.28 5.04 4.74 0.22 0.40 4.25 2.30 4.49 159.54
176 499 321 994 202 21 304 78 2181 16 36 129 784 8 279 229 11 14 201 118 211 7852
EU 5.42 4.99 8.01 17.74 5.01 1.25 7.84 2.79 40.97 0.67 0.80 2.37 12.20 0.32 5.47 4.42 0.29 0.42 3.55 2.04 4.85 153.59
20 944 21 295 37 427 85 508 22 493 6096 35 161 11 641 183 021 2313 3025 10 359 67 944 982 28 282 20 263 1316 1576 16 124 10 016 21 666 707 159
aIncluding unspeciﬁed liver cancers (ICD 10th C22.9 and C78.7).
HL, Hodgkin lymphoma; ICD, International Classiﬁcation of Diseases; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; EU, European Union.
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Table 2. Overall age-adjusted (world population) mortality rates (ﬁrst row) and average annual number of deaths (second row) from selected cancers per 100 000 women in 35 European countries plus the
European Union in 2005–2009 (unless otherwise speciﬁed)
Oral cavity/
pharynx
Esophagus Stomach Intestines Liver Gall-
bladder
Pancreas Larynx Lung Bone Connective/soft
tissue sarcomas
Skin Breast Uterus Ovary Bladder Kidney Thyroid HL NHL MM Leukemias All
neoplasms
ICD X C00–C14 C15 C16 C17–C21,
C26
C22.0–
C22.7
C23–C24 C25 C32 C33–
C34
C40–
C41
C47, C49 C43–
C44
C50 C53–
C55
C56–
C57.4
C67 C64–C66,
C68
C73 C81 C82–C85,
C96
C88,
C90
C91–C95 C00–D48
Austria 1.25 0.61 3.65 8.49 1.96 1.48 6.14 0.19 12.57 0.23 0.66 1.58 15.81 4.44 5.23 1.05 1.93 0.38 0.17 2.21 1.30 3.01 86.84
111 59 450 1095 219 189 712 16 1134 17 56 166 1552 439 532 160 235 48 18 271 165 340 9426
Belarus (2007–2009) 0.72 0.30 8.96 7.19 1.44a – 3.12 0.09 3.51 – – 1.46 13.88 7.70 5.18 0.47 – – – 1.36 1.17 3.48 77.00
67 34 965 803 149a – 344 9 367 – – 133 1230 681 470 63 – – – 136 119 325 7538
Belgium 1.13 1.35 2.07 10.29 1.56 0.61 5.00 0.22 13.03 0.31 0.71 1.40 19.82 4.10 5.38 1.29 1.76 0.34 0.24 2.01 1.34 3.02 89.43
121 173 322 1634 220 99 733 25 1425 32 75 167 2268 516 670 222 252 48 25 312 218 409 11 705
Bulgaria 1.26 0.39 5.85 11.86 3.51 1.09 4.37 0.29 7.46 0.76 0.23 1.39 15.81 10.37 5.79 1.11 1.32 0.31 0.36 1.43 0.49 2.80 88.06
103 36 584 1165 328 106 415 24 602 51 14 125 1272 754 448 110 115 31 22 107 40 197 7412
Croatia 0.97 0.61 5.71 13.23 3.02a 2.65 5.39 0.31 11.74 0.71 0.29 2.18 17.38 6.28 6.42 1.26 1.82 0.40 0.28 2.34 1.42 3.27 99.68
49 36 341 813 183a 165 313 15 589 32 15 113 883 320 305 84 110 24 10 123 79 164 5412
Czech Republic 1.34 0.64 4.22 13.66 1.11 4.08 7.17 0.21 13.00 0.42 0.52 1.70 15.41 7.25 6.85 1.53 3.59 0.39 0.26 2.09 1.38 3.24 105.44
139 74 524 1808 128 536 901 22 1447 40 48 198 1754 774 724 210 453 54 27 263 177 379 12 493
Denmark (2005–2006) 1.68 1.91 2.60 14.47 0.99 0.81 6.28 0.35 29.98 0.45 0.86 2.12 21.31 5.12 7.41 2.31 2.29 0.37 0.24 2.45 1.35 2.91 124.41
99 118 163 1080 60 53 408 19 1682 18 41 117 1253 300 418 176 145 23 11 164 98 200 7777
Estonia 1.17 0.43 8.37 11.22 1.81 1.39 5.80 0.17 8.09 0.30 0.65 2.41 15.65 8.13 7.01 1.07 2.56 0.48 0.23 1.69 1.40 3.84 94.08
19 8 149 229 32 27 112 3 140 5 9 39 232 124 114 24 46 11 3 33 27 66 1629
Finland 0.90 0.97 3.28 7.89 1.92 1.65 6.52 0.08 8.86 0.16 0.74 1.36 14.26 3.26 5.31 0.72 2.03 0.33 0.15 2.85 1.68 2.27 77.09
61 76 225 612 134 129 486 5 572 7 39 90 836 222 329 71 156 29 7 226 130 148 5303
France 1.17 0.97 1.90 9.13 1.69 0.72 4.79 0.22 10.33 0.38 0.64 1.30 16.95 4.25 4.71 1.04 1.47 0.26 0.20 2.17 1.39 2.87 82.04
744 747 1718 8849 1396 729 4172 141 6582 224 384 993 11 476 3067 3368 1145 1285 254 120 1997 1337 2451 64 616
Germany 1.24 1.04 3.72 10.09 1.48 1.63 5.88 0.21 12.76 0.25 0.67 1.27 17.08 3.86 5.33 1.22 2.13 0.34 0.16 2.10 1.42 2.88 89.04
1139 1124 4742 14 025 1805 2215 7408 197 12 379 192 563 1362 17 159 3985 5679 1907 2756 453 156 2673 1847 3362 102 290
Greece 0.58 0.27 3.30 7.77 3.08a 0.93 4.21 0.20 7.72 0.92 0.27 1.01 14.65 3.36 4.10 1.00 1.13 0.27 0.73 0.84 1.03 3.44 73.33
82 43 498 1266 510a 147 642 30 1010 107 29 137 1895 434 512 178 176 42 94 116 166 516 10 307
Hungary 2.92 0.96 5.70 16.56 2.27a 3.18 6.83 0.65 24.41 0.29 0.56 1.89 18.69 7.70 5.90 1.71 2.19 0.41 0.18 2.19 1.10 3.84 123.41
273 98 754 2238 293a 451 884 59 2526 26 53 222 2093 780 656 236 277 57 16 264 140 438 14 383
Iceland 1.07 1.22 2.89 8.23 1.22 0.71 5.73 – 25.34 0.48 0.50 2.06 16.36 3.00 5.21 0.77 2.34 0.61 0.24 1.80 1.51 2.14 95.21
4 4 8 26 4 3 17 – 65 1 1 5 39 8 13 3 7 2 1 5 6 6 259
Ireland 0.96 2.84 3.29 11.56 1.86 0.79 5.50 0.22 18.58 0.24 0.62 1.80 20.50 5.46 7.77 1.33 1.96 0.32 0.26 2.82 1.59 2.73 105.73
35 118 130 471 75 32 218 8 668 8 18 70 679 172 255 59 71 12 9 111 65 105 3870
Italy (2006–2009) 0.96 0.47 4.35 10.12 1.55 1.98 5.16 0.18 9.44 0.40 0.61 1.21 16.02 3.57 4.42 0.93 1.31 0.38 0.31 2.35 1.54 3.07 84.62
784 434 4347 10 183 1519 1980 5027 150 7627 221 380 934 11 945 2822 3235 1148 1259 354 188 2195 1551 2576 74 410
Latvia 1.19 0.59 7.74 11.74 1.89a 0.98 5.82 0.20 6.47 0.51 0.65 2.28 17.26 9.71 7.97 1.00 2.64 0.55 0.40 2.06 1.15 2.99 97.55
30 18 237 385 61a 34 185 5 195 11 16 64 419 248 202 42 84 18 7 56 37 88 2755
Lithuania 0.95 0.65 7.25 10.92 0.75 1.27 4.80 0.20 5.62 0.45 0.63 1.93 16.59 10.99 7.53 1.02 2.59 0.44 0.38 1.69 1.49 3.65 94.34
35 25 306 491 32 59 215 6 231 13 19 73 571 360 264 54 112 19 12 74 62 137 3659
Luxembourg 1.14 1.08 2.81 10.58 1.27 0.36 4.83 0.36 13.44 0.18 0.40 1.14 15.38 4.60 5.34 1.19 0.89 0.27 0.43 1.98 1.53 3.29 86.11
5 5 14 66 8 3 30 2 62 1 2 6 75 23 27 8 6 2 1 12 9 19 456
Macedonia (2006–2009) 0.85 0.20 7.31 10.00 4.77 1.72 4.47 0.77 8.26 0.99 0.71 2.73 16.80 7.93 4.90 1.16 1.27 0.38 0.51 1.01 0.48 2.62 89.07
14 4 125 169 79 30 74 12 129 14 9 42 260 122 75 20 19 6 8 17 7 37 1409
Malta 1.25 0.84 2.78 11.00 0.79 0.65 5.35 0.49 5.37 0.31 0.75 0.75 19.89 5.03 6.90 1.85 2.10 0.40 0.47 2.55 1.17 2.81 84.96
5 4 13 49 4 3 25 2 21 2 1 3 77 21 28 12 9 2 2 11 5 10 359
Netherlands 1.15 2.17 2.92 13.71 0.85 0.93 5.98 0.26 21.38 0.37 0.67 2.14 19.73 3.56 5.74 1.62 2.49 0.34 0.23 2.58 1.43 2.86 105.37
192 410 580 2902 154 193 1157 43 3335 46 98 335 3265 628 983 355 466 68 36 502 300 516 19 010
Norway 0.90 0.81 2.77 13.65 1.09 0.50 5.81 0.07 17.66 0.25 0.58 2.63 13.66 4.54 6.92 1.39 1.56 0.36 0.11 2.31 1.82 2.43 93.13
48 48 167 851 56 35 339 4 837 12 24 129 664 232 326 101 99 23 6 143 114 142 5097
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Table 2. Continued
Oral cavity/
pharynx
Esophagus Stomach Intestines Liver Gall-
bladder
Pancreas Larynx Lung Bone Connective/soft
tissue sarcomas
Skin Breast Uterus Ovary Bladder Kidney Thyroid HL NHL MM Leukemias All
neoplasms
Poland 1.26 0.75 4.68 11.40 2.20a 3.12 5.17 0.50 15.21 0.48 0.43 1.83 14.61 8.77 7.11 1.33 2.33 0.45 0.38 1.81 1.47 3.20 106.71
474 295 1971 5017 957a 1355 2154 167 5447 158 127 761 5237 3062 2472 617 972 194 121 713 609 1217 41 498
Portugal 0.92 0.55 6.67 10.90 1.16 0.97 3.42 0.12 5.74 0.45 0.62 1.24 13.71 5.47 3.17 1.05 0.82 0.36 0.26 2.33 1.30 2.66 74.54
110 87 934 1672 169 155 512 14 703 44 65 180 1543 648 380 197 122 56 25 311 190 338 9735
Romania 1.19 0.46 5.31 9.83 3.88a 1.13 4.54 0.31 8.66 0.94 0.50 1.56 15.78 13.48 5.11 1.06 1.25 0.43 0.34 1.61 0.74 2.96 91.92
234 99 1247 2305 895a 267 1045 62 1793 173 91 346 3106 2387 968 283 266 96 55 303 156 533 18 832
Russia 1.08 0.84 10.06 12.74 2.35a – 4.57 0.15 5.55 – – 1.30 17.12 9.35 5.77 0.77 – – – 1.29 0.75 3.07 93.09
1561 1450 15 906 20 601 3617a – 7186 218 8495 – – 1710 22 851 12 310 7608 1401 – – – 1693 1051 3759 13 3816
Slovakia 1.39 0.59 5.05 14.20 2.62a 3.60 6.18 0.23 8.43 0.47 0.61 1.91 15.17 9.41 6.36 1.13 2.81 0.41 0.33 1.90 1.46 3.37 98.33
67 29 284 811 141a 203 339 11 418 20 24 97 739 443 300 68 147 25 13 100 79 160 5046
Slovenia 1.02 0.59 5.12 12.63 2.15a 2.56 6.09 0.26 12.76 0.41 0.42 2.82 17.43 5.97 6.56 1.56 2.13 0.27 0.17 2.49 1.62 3.03 98.54
22 16 140 354 58a 77 160 6 284 6 8 67 411 137 144 48 54 9 3 67 47 68 2460
Spain 0.87 0.48 3.50 9.48 1.89 1.16 3.99 0.16 6.31 0.35 0.59 1.04 12.68 3.91 3.92 1.07 1.18 0.31 0.23 1.95 1.30 2.50 70.97
446 252 2179 6088 1225 773 2350 72 2817 119 239 600 5969 1946 1811 822 679 186 105 1132 833 1330 38 993
Sweden 0.98 0.89 2.17 10.72 1.84a 2.67 6.60 0.08 15.59 0.23 0.81 2.03 14.17 4.16 6.11 1.23 2.17 0.31 0.13 2.22 1.66 2.69 90.82
110 109 279 1452 244a 331 830 8 1624 18 73 221 1483 479 630 194 283 46 15 308 230 323 10 906
Switzerland (2005–2007) 1.23 1.19 2.16 7.06 1.97a – 5.21 0.12 12.21 – – 1.41 15.77 3.24 5.01 1.20 1.58 – – 2.26 1.37 2.38 79.44
101 104 228 752 179a – 522 10 943 – – 117 1295 294 421 148 159 – – 244 146 227 7272
Ukraine (2005–2006/2008–
2009)
0.91 0.31 7.65 10.84 1.39 – 3.51 0.12 4.66 – – 1.38 17.79 10.07 5.77 0.59 – – – 1.17 0.60 3.05 85.35
438 176 3915 5851 678 – 1858 55 2365 – – 581 7948 4354 2472 369 – – – 483 270 1181 39 752
UK 1.08 3.04 2.29 10.69 1.52 0.54 5.02 0.23 20.53 0.29 0.65 1.63 18.39 4.11 6.63 1.69 1.96 0.26 0.26 2.68 1.52 2.53 102.95
727 2546 1997 9006 1155 432 3926 156 14 843 131 354 1112 12 109 2663 4304 1661 1454 211 142 2085 1276 1881 76 233
England and Wales 1.04 2.96 2.19 10.46 1.49 0.52 5.02 0.22 19.58 0.29 0.66 1.63 18.37 4.09 6.59 1.66 1.91 0.26 0.26 2.67 1.53 2.56 101.43
623 2204 1716 7860 1007 374 3488 132 12 593 116 313 979 10 731 2350 3788 1459 1256 190 124 1840 1126 1686 66 710
Northern Ireland 1.16 2.69 2.97 12.23 1.60 0.56 4.95 0.23 19.55 0.31 0.55 1.76 18.36 3.60 7.53 1.36 2.14 0.33 0.27 2.62 1.51 2.29 102.75
19 56 63 253 31 13 98 4 349 4 9 33 306 62 123 32 38 6 5 52 32 43 1905
Scotland 1.41 3.97 3.02 12.49 1.81 0.67 5.07 0.33 30.13 0.28 0.66 1.56 18.63 4.49 6.76 2.08 2.39 0.22 0.27 2.82 1.51 2.39 118.18
85 286 217 893 116 45 339 20 1901 11 32 99 1072 250 393 170 160 16 14 192 118 152 7618
EU 1.15 1.09 3.65 10.51 1.79 1.51 5.23 0.24 12.63 0.39 0.60 1.43 16.43 5.15 5.39 1.23 1.80 0.34 0.26 2.16 1.39 2.91 90.78
6162 7004 24 791 75 193 11 809 10 581 35 000 1254 69 510 1688 2823 8459 89 319 27 411 29 406 10 009 11 868 2342 1237 14 385 9804 17 793 55 5168
aIncluding unspeciﬁed liver cancers (ICD 10th C22.9 and C78.7).
HL, Hodgkin lymphoma; ICD, International Classiﬁcation of Diseases; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; EU, European Union
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Figure 1. Joinpoint analysis of trends in age-standardized (world population) mortality rates from 23 cancer sites plus all neoplasms (malignant and benign)
in the European Union, 1980–2009. Filled boxes represent men, all ages; open boxes represent men, 35–64 years; ﬁlled circles represent women, all ages; open
circles represent women, 35–64 years.
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Figure 2. Joinpoint analysis of trends in age-standardized (world population) mortality rates from all neoplasms (malignant and benign) and major cancer
sites (i.e. intestines, lung, breast, and prostate) in 24 selected European countries, 1980–2009. Filled boxes represent men, all ages; open boxes represent men,
35–64 years; ﬁlled circles represent women, all ages; open circles represent women, 35–64 years.
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multiple myeloma (APC = −1.6% in men and −2.1% in women
between 2003 and 2009).
Figure 2 presents the results of the joinpoint analysis of trends
in mortality rates (at all ages and truncated 35 to 64 years) from
all neoplasms (malignant and benign) and major cancer sites,
i.e. intestines, lung, breast, and prostate, in 24 selected European
countries between 1980 and 2009. Since the late 1980s/early
1990s, mortality from all neoplasms has been declining in most
Figure 2. Continued
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European countries. The reductions started earlier (since the
early 1980s) in some western and northern countries, such as
Austria, Denmark, Finland, Germany, Sweden, and the UK, and
more recently (since the early 2000s) in Hungary and Poland,
while in Bulgaria and Romania, mortality has been leveling off
over the last years only. In most countries, trends in total cancer
mortality were more favorable in middle-aged populations.
Cancer mortality has been converging in men and women from
Figure 2. Continued
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several countries, and in most recent years truncated rates in the
two sexes were very similar in Nordic countries and the UK.
Mortality has been declining for cancer of the intestines
(chieﬂy colon and rectum) since the early 1990s in most
northern and western countries, including France, Germany,
Italy, and the UK, as well as in the Czech Republic, which,
however, started from exceedingly high rates (Figure 2).
Mortality from intestinal cancer has still been increasing or only
Figure 2. Continued
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leveling off over most recent calendar years, particularly in men,
in some central and eastern European countries, such as Poland,
Romania, and Russia, but also in Greece and Portugal, where
rates were relatively low in the past. In most countries, mortality
from intestinal cancer has been more favorable in women, with
earlier and larger (proportional) declines.
Mortality from lung cancer in men has long been declining in
Austria, Finland, the Netherlands, Switzerland, and the UK
Figure 2. Continued
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(Figure 2). Long-term declines in male lung cancer were
observed in Sweden, too, where lung cancer has always been
low. Male mortality rates had a peak in the mid/late 1980s in
most other northern and western European countries and in the
1990s in several central and eastern countries, leveling off or
declining thereafter. Only in Portugal and Romania, overall
male lung cancer mortality was still increasing over recent years.
Portuguese rates were, however, comparatively low (28.6/
100 000). Overall and middle-age mortality from lung cancer in
women increased up to recent calendar years in most European
countries, the highest recent rises being in Hungary, France, and
Spain. In contrast, in the Netherlands and the UK, which had
high rates in the past, but also in Sweden, female lung cancer
mortality has leveled off in the last few years, particularly in
middle-aged women.
Mortality from breast cancer started to decline between the
late 1980s and the early 1990s in most European countries,
including those (Spain, Sweden, and Norway) that already had
relatively low rates (below 20/100 000) in the 1990s (Figure 2).
The declines were generally more marked in relative terms in
middle-aged women. Only in Bulgaria, Latvia, Russia, and
Ukraine (which had comparatively low rates in the past) overall
breast cancer rates have not declined in the last two decades,
although trends were more favorable in the middle-aged. This
led to a reduction of the difference in breast cancer mortality
across Europe, most national overall rates being between 13 and
19/100 000 over most recent calendar years.
Mortality rates from prostate cancer have been leveling off
since the mid-1990s in most countries of western Europe,
including Italy, which had comparatively low rates in the past
(Figure 2). Declines in mortality rates have been observed more
recently in the Czech Republic, Hungary, and Latvia, whereas
mortality has still been rising over the most recent calendar
years in other central and eastern European countries, including
Poland, Romania, Russia, and Ukraine, which, however,
maintained comparably low rates.
Supplementary Figure S1, available at Annals of Oncology
online, gives the corresponding trends for other selected cancer
sites, i.e. oral cavity or pharynx, esophagus, stomach, gall-
bladder, pancreas, larynx, bone, connective and soft tissue
sarcomas, skin, uterus, ovary, testis, bladder, kidney, thyroid,
Hodgkin lymphoma, non-Hodgkin lymphoma, multiple
myeloma, and leukemias.
discussion
In the interpretation of the data presented, problems related to
random variation, which are greater in relation to smaller
populations and rarer cancers, should be considered. There are
also problems of death certiﬁcation reliability and accuracy
(validity) due to the difﬁculties in ascertaining and certifying the
cause of death for selected cancer sites [17, 18]. For some
countries, coverage of the population is incomplete, and for that
reason we excluded Albania, Macedonia, the Republic of
Moldova, and several countries of the former Soviet Union
whose national coverage was <90% [6]. Low-quality cause-of-
death data have also been reported for some other countries,
such as Greece, Bulgaria, and Poland [19]. However, for most
countries considered, death certiﬁcation is sufﬁciently reliable to
permit meaningful inference on trends particularly for common
cancer sites, including stomach, intestines, lung, and breast
particularly under age 65 years. For a few cancer sites (including
bone, soft tissue sarcomas, prostate, multiple myeloma, and
other lymphoid neoplasms), diagnosis and certiﬁcation may be
inﬂuenced by the availability of diagnostic techniques and the
accuracy of death certiﬁcation.
This up-to-date analysis conﬁrms the persistence of favorable
trends in mortality from cancer in most European countries [3].
Total cancer mortality in EU men reached a peak at 187/
100 000 in1988 to decline by 20% in 2009 (149.2). Over the
same calendar period, cancer mortality in women steadily
declined by 16%, in the absence, however, of a peak in the late
1980s. Such a fall in cancer mortality in the EU was similar to
that observed in the USA for women (−16% from 1991 to
2009), but it was smaller for men (−24%) [20].
The major contributors to the decline in total cancer
mortality in men were the steady fall in lung cancer and other
tobacco-related neoplasms since the late 1980s, along with the
persistent decline in gastric cancer mortality, and the decline
since the early 1990s in mortality from cancers of the intestines
and prostate. In women, the fall in total cancer mortality has
been mainly due to the decline in intestinal and breast cancer
mortality since the late 1980s and the long-term reduction in
mortality from cancer of the (cervix) uterus. Only mortality
from female lung cancer, pancreatic cancer, and soft tissue
sarcomas in both sexes was still increasing (or not declining),
while mortality from multiple myeloma has started to decline in
the most recent calendar years.
Trends in cancer mortality have been less favorable in central
and eastern European countries, where mortality (overall and
from major sites) has been increasing up to the late 1990s/early
2000s. Consequently, over recent calendar years, there still was a
twofold difference between the highest rate in male cancer
mortality in Hungary (253.2/100 000) and the lowest one in
Sweden (112.9/100 000), and a 1.7-fold one in women (between
124.4 in Denmark and 71.0/100 000 in Spain).
The favorable trends in cancer mortality can be largely
attributed to favorable changes in the exposure to speciﬁc
environmental and lifestyle risk factors [1, 2, 21], mainly
the reduction in tobacco consumption in subsequent
generations of European men (with a favorable impact on lung
and other tobacco-related neoplasms) [22, 23], the reduction in
occupational exposure to carcinogens (lung and bladder cancer)
[24], a better food conservation, and the control of Helicobacter
pylori infection (gastric cancer) [25], and a more afﬂuent
and varied diet (gastric, but probably colorectal cancer)
[26–28]. Alcohol consumption has been steadily declining over
the last decades in countries from southern Europe, with a
consequent favorable impact on oral, pharyngeal, esophageal,
and laryngeal cancers in those countries. Mortality from
alcohol-related cancers remains, however, exceedingly high in
countries from central and eastern Europe [22, 29].
Early diagnosis through opportunistic and organized
screenings has likely had a role on colorectal (through fecal
occult blood test, ﬂexible sigmoidoscopy, and colonoscopy) [28,
30], breast (mammography) [31–33 ], and possibly prostate
cancer (prostate-speciﬁc antigen test) mortality [34, 35],
although the quantiﬁcation of the role of diagnostic screening
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on mortality from those neoplasms (mostly for prostate cancer)
is still under debate [32, 36–41]. Screening has been the main
responsible factor for the long-term decline in cervical cancer
(through the PAP smear test and, more recently, the human
papilloma virus test) particularly in countries from western and
northern Europe [42], while the less widespread and/or later
adoption of cervical cancer screening in central and eastern
countries is likely to largely explain the less favorable
trends and the persistent exceedingly high rates in those
countries [4, 43, 44].
Improvements in disease treatment and management are
likely to have appreciably contributed to the favorable trends in
breast cancer (through hormonal therapies and chemotherapy,
advancement in radiotherapy and surgery) [31, 33, 45], but also
colorectal (chemotherapy and radiotherapy) [28, 30] and
prostate (androgen blockage, transurethral resection of the
prostate, and radiotherapy) [35, 41] cancer. The adoption of
newer therapies has also had a marked impact toward the
reduction in mortality from a few other neoplasms amenable to
treatment, including testicular cancer [35, 46], Hodgkin
lymphoma [47], and leukemias [48]. Trends in mortality from
those neoplasms have been less favorable in countries from
central and eastern Europe, probably due to delays in the
adoption of modern integrated therapies in those areas of the
continent [5, 47]. With reference to testicular cancer, in several
countries of western and northern Europe where treatments for
this neoplasm (namely platinum-based therapies) have been
available since the 1970s and where mortality from the disease
has long been declining, a leveling off in the rates has been
observed in most recent calendar years, suggesting that a plateau
in mortality has been reached.
The persistent increase in mortality from lung cancer in
women from most European countries reﬂects the different
pattern of tobacco smoking in women when compared with
men, with a later spread in tobacco consumption [21, 49]. The
female lung cancer epidemic is still expanding in countries of
western (particularly France, Spain, and Switzerland) and
central/eastern Europe, where smoking prevalence in women
has only leveled off since the late 1990s, while the epidemic
seems to have reached a plateau in the UK and the Netherlands,
where smoking prevalence in women has been falling over the
last few decades [50]. We predicted a persistent rise in lung
cancer mortality in EU women, to reach a rate of 14.0/100 000
in 2015 [49].
The reasons for the unfavorable patterns in pancreatic cancer
in Europe (as in the USA and other developed countries of the
world) are not clearly understood [51, 52]. Diagnostic
improvements may partly or largely account for earlier rises.
The reduction in male tobacco smoking prevalence (the major
recognized risk factor for pancreatic cancer) [25] should have
played a favorable role on mortality from this neoplasm.
However, the increasing prevalence of overweight/obesity [53]
and consequent type II diabetes—other two major recognized
risk factors for pancreatic cancer [25]—over the last decades in
many European countries have likely unfavorably inﬂuenced
mortality from this neoplasm. Improved diagnosis and
certiﬁcation may also have contributed to the rising trends.
With the major exceptions of lung cancer in women and
pancreatic cancer in both sexes, in the last quinquennium
cancer mortality has declined moderately but steadily across
Europe. There are, however, persisting differences across
countries which require speciﬁc attention and intervention on
risk factor control, early diagnosis, and improved management.
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